The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-na ïve Metastatic Castration-resistant Prostate Cancer

Conclusions Enzalutamide provided clinically significant benefits in men with chemotherapy-naïve metastatic castration-resistant prostate cancer, with or without visceral disease, low- or high-volume bone disease, or lymph node only disease. Patient summary Patients with metastatic castration-resistant prostate cancer—including those with or without visceral disease or widespread bone disease—benefitted from enzalutamide, an active well-tolerated therapy. Enzalutamide provided meaningful clinical benefit to men with chemotherapy-naïve metastatic castration-resistant prostate cancer, with or without visceral disease. Patients without visceral disease particularly benefitted from enzalutamide, an active therapy with good tolerability that allowed for a long duration of treatment.
Source: European Urology - Category: Urology & Nephrology Source Type: research